MTOR and cancer: Besides the traditional pan-PI3K and dual PI3K/mTOR inhibitors, another newer class of PI3K inhibitors, known as isoform-selective PI3K inhibitors, has also been starting to gain traction over the past few years as there is increasing evidence that supports the notion that different PI3K isoforms serve non-overlapping functions in cancer cells in a context-dependent fashion [159].